Trials / Completed
CompletedNCT00548587
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Clinical Events and Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 600 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E5555 | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-04-01
- Completion
- 2009-08-01
- First posted
- 2007-10-24
- Last updated
- 2016-02-04
Locations
2 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00548587. Inclusion in this directory is not an endorsement.